MedTrace Logo

First in Man Study With SLV342

NCT00985478 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2011-08-25

No results posted yet for this study

Summary

First in man study with single and multiple rising doses with SLV342

Conditions

  • Pharmacokinetics

Interventions

DRUG

SLV342

25 mg once daily - Maximal Tolerated Dose

DRUG

placebo

matching placebo

Sponsors & Collaborators

  • Quintiles, Inc.

    collaborator INDUSTRY

  • Abbott Products

    lead INDUSTRY

Principal Investigators

  • Ingrid Meuwsen, MS · Abbott Healthcare Products B.V

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2010-06-30
Completion
2010-06-30

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00985478 on ClinicalTrials.gov